On the contrary, doxorubicin treatment of HT29-dx and HT29-iNOS- cells failed to induce CRT translocation, did not change the uptake of the tumour and had no effect on the alloantigen presenting activity of DCs. The gene discussed is CALR; the disease is neoplasm.